Vol. 17/No. 19

Technology is in the works that would allow medically useful personal health metrics to be collected by sensors that can be incorporated into clothing, accessories, or skin patches, and then transmitted electronically for analysi

Robert C. Bast Jr, MD, who led the development of the first clinically relevant blood-based biomarker for ovarian cancer, was honored in the Gynecologic Malignancies category with a 2015 Giants of Cancer Care® award, a program that OncLive launched to recognize leaders in the field.

Dmitry I. Gabrilovich, MD, PhD, provides perspective on understanding the role of the tumor microenvironment in the regulation of the immune response in cancer, with a focus on myeloid cells.

As the role that the tumor microenvironment plays in the development of cancer becomes increasingly well understood, a new player has emerged: myeloid-derived suppressor cells.

OncLive is pleased to announce that the Society for Immunotherapy of Cancer (SITC) has joined the OncLive Strategic Alliance Partnership program, a collaborative effort to bring up-to-date clinical information to practicing oncology specialists.

Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.

Historically, patients with advanced renal cell carcinoma have had few treatment options, but several targeted agents and one immunotherapy, the checkpoint inhibitor nivolumab, have been approved within the past 5 years, considerably expanding the RCC treatment arsenal. In the frontline setting, targeted agents are often the go-to therapy.

Two headgear items, a system of applying electromagnetic currents to patients with glioblastoma and a cooling cap for individuals undergoing chemotherapy for breast cancer, are early entries in the field.

The SPINET trial is an international, phase III, randomized, double-blind study evaluating the efficacy and safety of lanreotide (Somatuline Depot) plus best supportive care compared with placebo plus best supportive care in patients with well-differentiated, metastatic and/or unresectable, typical or atypical lung neuroendocrine tumors.

Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.

Perhaps oncologists know that having a detailed understanding of population-based survival statistics is very different from such knowledge of the future clinical course of an individual patient.